Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sorin Group divests vascular therapy business unit
Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3 million decrease against revenues of $30.6 million for the nine months ended March 31,
Revenues for the nine months ended March 31, 2009 were $29.3 million, a $1.3 million decrease against revenues of $30.6 million for the nine months ended March 31,
According to the company, the availability of PreNexa avoids the potential of being exposed to oceanborne pollutants like mercury because it derives its DHA from microalgae, a direct
The Phase II study is an open-label, multi-national, optimal two-stage design to be conducted in the US and Taiwan. PharmaEngine plans to enroll metastatic pancreatic cancer patients who
The vote was 12 to zero in favor of approval, with one panel member abstaining. If approved in the US by the FDA, febuxostat will be the first
This patent is the ninth US patent granted to ScinoPharm and the second patent for one of the company’s high demand oncology products, irinotecan hydrochloride. ScinoPharm has already
The single-center, in-clinic, randomized, double-blinded study enrolled a total of 18 healthy male subjects. Using a three-period cross-over design, subjects received two intradermal injections of capsaicin at 30
In connection with the settlement and license agreement, Medicis and Impax have agreed to terminate all legal disputes between them relating to Solodyn extended release tablets. Additionally, under
The investigative new drug (IND) application is to enable a Phase Ib study of triphendiol in combination with gemcitabine in patients with unresectable, locally advanced or metastatic pancreatic
The Phase IIa human clinical trial will involve 150 vaccines and 75 placebo participants. The vaccine regimen employs a two-component ‘prime-boost strategy’. Trial participants will first be administered
Study 102 will establish multiple dose pharmacokinetics (PK) and expand the safety database for MSI-1436 in a population of overweight and obese adult type 2 diabetic subjects who